BTAI - BioXcel Therapeutics Inc. (BTAI) Q4 2023 Earnings Call Transcript
2024-03-12 11:00:22 ET
BioXcel Therapeutics, Inc. (BTAI)
Q4 2023 Earnings Conference Call
March 12, 2024 8:00 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer
Vince O'Neill - Chief of Product and Development Medical Officer
Richard Steinhart - Chief Financial Officer
Robert Risinger - Chief Medical Officer, Neuroscience
Matt Wiley - Chief Commercial Officer
Conference Call Participants
Greg Harrison - Bank of America
Robyn Karnauskas - Truist Securities
Graig Suvannavejh - Mizuho Securities
Sumant Kulkarni - Canaccord Genuity
Ram Selvaraju - H.C. Wainwright
Colin Bristow - UBS
Samir Devani - Rx Securities
Presentation
Operator
Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will include an update on the company's late stage clinical programs and the discussion of financial results for the fourth quarter and full-year 2023. At this time, all participants are in listen-only mode. [Operator Instructions] After the formal remarks, there will be a question-and-answer session. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in those forward-looking statements.
Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2023, which can be found at www.bioxceltherapeutics.com or on www.sec.gov, and which will be updated in its annual report on Form 10-K for the quarter ended December 31, 2023. As a reminder, today's conference is being recorded.
Speaking on today's call are Dr. Vimal Mehta, Chief Executive Officer; Dr. Vince O'Neill, Chief of Product Development and Medical Officer; and Richard Steinhart, Chief Financial Officer. They will be joined in the Q&A session by Frank Yocca, Chief Scientific Officer; Matt Wiley, Chief Commercial Officer; and Dr. Rob Risinger, Chief Medical Officer of Neuroscience....
BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript